A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder
Phase of Trial: Phase II/III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Trigriluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 22 Jan 2019 Planned End Date changed from 31 Dec 2019 to 18 Nov 2020.
- 22 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 18 Nov 2019.
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the dosing for this trial was commenced in December 2017.